1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Genetic conditions
  5. Cystic fibrosis

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance [TA276] Published date: 27 March 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technologies
  • 4 Evidence and interpretation
  • 5 Implementation
  • 6 Related NICE guidance
  • Appendix A: Appraisal Committee members and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Update information
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download
    • Save
    • Save as PDF
    • Save as ePub
    • Save as eBook

Guidance

  • Next

6 Related NICE guidance

6 Related NICE guidance

  • Mannitol dry powder for inhalation for treating cystic fibrosis (2012) NICE technology appraisal guidance 266.

  • National Institute for Health and Care Excellence (NICE)

  • Next
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • NICE and the public
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions
  • Privacy notice

© NICE [year]. All rights reserved. Subject to Notice of rights.